Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage
Veris Health completes pilot program with The Ohio State’s James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor
Ongoing initiatives position PAVmed to preserve Nasdaq listing
NEW YORK, Nov. 14, 2024 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three months ended September 30, 2024.
Lucid has reported record quarterly revenue for its EsoGuard® product and has completed a clinical evidence package for imminent submission to formally seek Medicare coverage. This is a significant milestone for the company as Medicare coverage would greatly increase access to this important diagnostic tool.
Veris Health has completed a successful pilot program with The Ohio State’s James Cancer Hospital and is now focusing on securing financing to relaunch the development of its implantable monitor. This device has the potential to revolutionize patient monitoring and improve outcomes for cancer patients.
PAVmed is actively working on initiatives to preserve its Nasdaq listing, demonstrating its commitment to maintaining its status as a publicly traded company. The company’s leadership is dedicated to ensuring the continued success and growth of PAVmed and its subsidiaries.
Conference Call and Webcast
A conference call and webcast will be held today, November 14th at 8:30 AM EST. Investors and interested parties can access the webcast on the Company’s website at pavmed.com.
How will this affect me?
As a potential investor, the positive updates from PAVmed, Lucid, and Veris indicate that the companies are making progress and experiencing growth. This could present investment opportunities and potential for financial gains in the future.
How will this affect the world?
The advancements and developments made by PAVmed, Lucid, and Veris have the potential to have a significant impact on the medical technology industry. Improved diagnostic tools and patient monitoring devices can lead to better healthcare outcomes for patients around the world.
Conclusion
The recent updates from PAVmed, Lucid, and Veris demonstrate the companies’ dedication to innovation and growth in the medical technology sector. These developments have the potential to benefit both investors and patients globally, positioning the companies for continued success in the future.
